The comparative study will evaluate the potential increase in survival rates, thrombin levels and in vivo recovery of Factor VIIa-CTP.
The study reported that Factor VIIa-CTP showed superior survival rate over a longer time period following a bleeding challenge, superior and longer-lasting generation of thrombin, a key pro-clotting enzyme and higher in vivo recovery.
Prolor CEO Abraham Havron said the preclinical hemophilia studies suggested that Factor VIIa-CTP may offer an improved therapeutic option for hemophiliacs by reducing the frequency of injections, controlling bleeding and improving quality of life.
Factor VIIa-CTP has demonstrated positive results in an earlier comparative study compared to commercially available Factor VIIa.